BiotechTube
BioTools

BioTools

Boca Raton, United States· Est.
biotools.us
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

BioTools is a privately held analytical instrumentation and contract research organization (CRO) founded in 2002, headquartered in West Palm Beach, Florida. The company has developed a proprietary platform of chiroptical spectroscopy instruments (Vibrational Circular Dichroism and Raman Optical Activity) that enable rapid, precise analysis of molecular chirality and biomolecular structure. With a global distributor network and over 80 top pharma clients, BioTools serves the critical quality control and R&D needs of the biopharmaceutical industry, positioning itself as a niche leader in structural characterization.

DiagnosticsProteomics

Technology Platform

Proprietary chiroptical spectroscopy instruments (Vibrational Circular Dichroism - VCD and Raman Optical Activity - ROA) for determining molecular chirality and biomolecular structure.

Funding History

2
Total raised:$10M
Series A$8M
Seed$2M

Opportunities

The rapid growth of complex biologics and advanced therapeutic modalities creates expanding demand for sophisticated structural characterization tools.
Geographic expansion, particularly in the Asian market through BioTools China, presents a significant growth vector.
The high-margin Contract Research Organization (CRO) services business is scalable and provides recurring revenue.

Risk Factors

Operating in a specialized niche limits total addressable market and creates dependence on pharmaceutical R&D budgets.
The company faces competition from evolving alternative analytical techniques like cryo-EM and advanced NMR.
International operations and reliance on key scientific personnel present execution and continuity risks.

Competitive Landscape

BioTools competes in the analytical instrumentation space against large players like Thermo Fisher, Agilent, and Waters, though it holds a niche leadership position in chiroptical spectroscopy. Its primary competition comes from alternative techniques for structure determination (X-ray, NMR, cryo-EM) rather than direct instrument competitors. Its deep expertise, specialized technology, and established user base among top pharma create a defensible moat.

More companies in Proteomics & Protein Engineering →More companies in United States →